Vaxart (VXRT) reported positive 12-month safety data from its Phase II-B Sentinel cohort (400 participants), supporting the program’s risk profile. The company reiterated it remains on track to disclose top-line results from the larger ~5,000-participant main cohort in 1H 2027. This is a constructive clinical update, but it is primarily safety-focused ahead of efficacy/primary topline data.
Vaxart (VXRT) reported positive 12-month safety data from its Phase II-B Sentinel cohort (400 participants), supporting the program’s risk profile. The company reiterated it remains on track to disclose top-line results from the larger ~5,000-participant main cohort in 1H 2027. This is a constructive clinical update, but it is primarily safety-focused ahead of efficacy/primary topline data.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
